Document:

Exhibit 10.7

 

VIREO HEALTH INTERNATIONAL, INC.

INCENTIVE STOCK OPTION AGREEMENT

 

I.            NOTICE
OF GRANT

 

	Name of Optionee:	Kyle Kingsley
	 	 
	Number of Shares:	51,008 Super Voting Shares (the “Shares”)
	 	 
	Date of Original Grant:	May 1, 2018
	 	 
	Date of Replacement Grant:	March 18, 2019
	 	 
	Exercise Price per Share:	$3.30
	 	 
	Expiration Date:	May 1, 2023 (five years after Date of Original
Grant)

 

Exercise Schedule: Subject to Section 4
hereof and the terms of the Vireo Health International, Inc. 2019 Equity Incentive Plan (the “Plan”),
45,008 of the Shares covered by the Option are vested and immediately exercisable, an additional 1,500 of the Shares covered by
the Option shall become exercisable and vest on March 31, 2019, and an additional 375 of the Shares covered by the Option
shall become exercisable and vest on the last day of each subsequent calendar quarter, such that 100% of the Shares covered by
the Option shall be exercisable and vested on June 30, 2022. In no case shall greater than 100% of the Shares covered by the
Option vest.

 

This is an Incentive Stock Option Agreement
(the “Agreement”), by and between Vireo Health International, Inc., a British Columbia corporation
and successor to Vireo Health, Inc. (the “Company”), and the optionee identified above (“Optionee”),
entered into and effective as of date of grant identified above (the “Grant Date”). Any capitalized term
that is not defined in this Agreement shall have the meaning set forth in the Plan as it currently exists or as it is amended in
the future.

 

The Option being granted under this Agreement
is being issued in exchange for all options held by Optionee by virtue of one or more grants made to Optionee by a predecessor
entity to the Company. All such options are listed on Schedule A to this Agreement and are extinguished by virtue of the grant
of the Option.

 

II.           BACKGROUND

 

1.            The
Company has adopted and maintains the Plan authorizing the Administrator to, among other things, grant Incentive Stock Options
to certain Employees, Directors, Consultants and other persons providing services to the Company and its Subsidiaries.

 

2.            The
Administrator has determined that Optionee is eligible to receive an Award under the Plan in the form of an Option, as further
described in this Agreement.

 

    

     

    

 

III.         AGREEMENT.
Subject to the Plan, the Company hereby grants the Option to Optionee under the terms and conditions as follows.

 

11.          Grant
of Option. The Company hereby grants to Optionee an Option to purchase the Shares specified above, according to the terms and
subject to the conditions hereinafter set forth and as set forth in the Plan. The Option is intended to be an “incentive
stock option” as that term is defined in Section 422 of the Code and is subject to the $100,000 limitation described
in Section 6(c) of the Plan, including the provisions of that Section 6(c) that treat any portion of the Option
that exceeds such limitation, or does not otherwise qualify as an incentive stock option, as a Nonstatutory Stock Option that is
not an incentive stock option but otherwise exercisable on, and subject to, the same terms as the Option.

 

12.          Exercise
Price per Share. The Exercise Price per Share shall not be less than the Fair Market Value per Share as of the Grant Date,
or if Optionee owns stock representing greater than 10% of the voting power of the Company or any Parent or Subsidiary (a “10%
Owner”), 110% of the Fair Market Value per Share as of the Grant Date, as may be further adjusted pursuant to the
Plan.

 

3.            Expiration.
The Option shall expire at 5:00 p.m. Central Time on the earliest of (i) the Expiration Date (which date may be no later
than ten years after the Grant Date, or, for a 10% Owner, five years after the Grant Date), (ii) upon the expiration of any
termination set forth in Section 6(f) of the Plan, or (iv) pursuant to Section 13(a) or (c) of the
Plan; provided, that unless otherwise provided by the Administrator, if on the date of termination Optionee is not vested as to
the entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan.

 

4.            Vesting
and Exercise.

 

4.1            Vesting
Schedule. The Option will vest and become exercisable as to the number of Shares and on the dates specified in the Notice of
Grant above, but only if Optionee is employed by the Company on such dates. The exercise schedule will be cumulative, meaning that
to the extent the Option has not been exercised and has not expired, terminated, or been cancelled, the Option may be exercised
to purchase all or any portion of the Shares available under the exercise schedule.

 

4.2            Change
in Control. If a Change in Control occurs, effective upon such Change in Control, the Option shall be treated as determined
by the Administrator under Section 13(c) of the Plan.

 

4.3            Termination
of Relationship as a Service Provider. If Optionee ceases to be a Service Provider, other than upon Optionee’s termination
as the result of Optionee’s Disability or death, the Option shall be treated as set forth under Section 6(f)(ii) of
the Plan.

 

4.4            Disability
or Death of Optionee. If Optionee ceases to be a Service Provider as a result of Optionee’s death or Disability, the
Option shall be treated as set forth under Section 6(f)(iii) or (iv) of the Plan, respectively.

 

5.            Manner
of Option Exercise.

 

5.1            Notice.
This Option may be exercised by Optionee in whole or in part from time to time, subject to the conditions contained in the Plan
and in this Agreement, by delivery, in person, by electronic transmission, or through the mail, to the Company at its principal
executive office in Minneapolis, Minnesota (Attention: Chief Financial Officer), of a written notice of exercise. Such notice must
be in a form satisfactory to the Administrator, must identify the Option, must specify the number of Shares with respect to which
the Option is being exercised, and must be signed by the person so exercising the Option. Such notice must be accompanied by payment
in full of the total exercise price of the Shares purchased based on the Exercise Price per Share. In the event that the Option
is being exercised, as provided by the Plan and Section 6 below, by any person or persons other than Optionee, the notice
must be accompanied by appropriate proof of right of such person or persons to exercise the Option.

 

    

     

    

 

5.2            Payment.
At the time of exercise of this Option, Optionee shall pay the total exercise price of the Shares to be purchased entirely in cash
(including a check, bank draft or money order, payable to the order of the Company); provided, however, that the Administrator,
in its sole discretion and to the extent permitted by law, may allow such payment to be made, in whole or in part, through a cashless
exercise in which Optionee simultaneously exercises the Option and sells all or a portion of the Shares thereby acquired; by delivery
to the Company of unencumbered Shares having an aggregate Fair Market Value on the date of exercise equal to the exercise price
of such Shares; or by authorizing the Company to retain, from the total number of Shares as to which the Option is exercised, that
number of Shares having a Fair Market Value on the date of exercise equal to the exercise price for the total number of Shares
as to which the Option is exercised.

 

5.3            Delivery
of Certificates. As soon as practicable after the effective exercise of the Option, Optionee shall be recorded on the stock
transfer books of the Company as the owner of the Shares purchased, and the Company shall deliver to Optionee one or more duly
issued stock certificates evidencing such ownership, electronic delivery of such Shares to a brokerage account designated by such
person, or book-entry registration of such Shares with the Company’s transfer agent. Notwithstanding anything to the contrary
in this Agreement, no certificate, electronic delivery or book-entry registration representing the Shares distributable under the
Plan shall be issued and delivered unless the issuance thereof complies with all applicable legal requirements including, without
limitation, compliance with the provisions of applicable state securities laws, the Securities Act and the Exchange Act. All Shares
so issued shall be fully paid and nonassessable.

 

6.            Transferability.
During the lifetime of Optionee, only Optionee or his/her guardian or legal representative may exercise the Option. The Option
may not be assigned or transferred by Optionee otherwise than by will or the laws of descent and distribution. The Option held
by any such transferee will continue to be subject to the same terms and conditions that were applicable to the Option immediately
prior to its transfer and may be exercised by such transferee as and to the extent that the Option has become exercisable and has
not terminated in accordance with the provisions of the Plan and this Agreement.

 

7.            No
Shareholder Rights. Neither Optionee nor any permitted transferee of this Option will have any of the rights of a stockholder
of the Company with respect to any Shares subject to this Option until a certificate evidencing such Shares has been issued, electronic
delivery of such Shares has been made to Optionee’s designated brokerage account, or an appropriate book entry in the Company’s
stock register has been made. No adjustments shall be made for dividends or other rights if the applicable record date occurs before
a stock certificate has been issued, electronic delivery of the Shares has been made to Optionee’s designated brokerage account,
or an appropriate book entry in the Company’s stock register has been made, except as otherwise described in the Plan.

 

    

     

    

 

8.            Restrictive
Covenants Agreement. As an inducement to the Company to enter into this Agreement and grant the Option to Optionee, Optionee
has executed or shall duly execute a Confidential Information, Intellectual Property Rights, Non-Competition and Non-Solicitation
Agreement (the “Restrictive Covenants Agreement”), in a form approved by the Company. Optionee acknowledges
and agrees that the Company’s execution of this Agreement and the grant of the Option to Optionee are conditioned upon Optionee
executing the Restrictive Covenants Agreement.

 

9.            Securities
Law and Other Restrictions. Notwithstanding any other provision of the Plan or this Agreement, the Company shall not be required
to issue, and Optionee may not sell, assign, transfer or otherwise dispose of, any Shares, unless (a) there is in effect with
respect to the Shares a registration statement under the Securities Act and any applicable state or foreign securities laws or
an exemption from such registration, and (b) there has been obtained any other consent, approval or permit from any other
regulatory body that the Administrator, in its sole discretion, deems necessary or advisable. The Company may condition such issuance,
sale or transfer upon the receipt of any representations or agreements from the parties involved, and the placement of any legends
on certificates representing the Option, as may be deemed necessary or advisable by the Company in order to comply with such securities
law or other restrictions.

 

10.          Tax
Withholding. The Company is entitled to (a) withhold and deduct from future fees or wages of Optionee (or from other amounts
that may be due and owing to Optionee from the Company), or make other arrangements for the collection of, all legally required
amounts necessary to satisfy any federal, state or local withholding and employment-related tax requirements attributable to the
Option, including, without limitation, the grant or exercise of this Option or a disqualifying disposition of any Shares, or (b) require
Optionee promptly to remit the amount of such withholding to the Company before acting on Optionee’s notice of exercise of
this Option. If the Company is unable to withhold such amounts, for whatever reason, Optionee agrees to pay to the Company an amount
equal to the amount the Company would otherwise be required to withhold under federal, state or local law.

 

11.          Adjustments.
Subject to the terms and conditions set forth in the Plan, in the event of any reorganization, merger, consolidation, recapitalization,
liquidation, reclassification, stock dividend, stock split, combination of shares, rights offering, divestiture or extraordinary
dividend (including a spin-off), or any other change in the corporate structure or shares of the Company, the Administrator, in
order to prevent dilution or enlargement of the rights of Optionee, shall make appropriate adjustment (which determination shall
be conclusive) as to the number and kind of securities or other property (including cash) subject to, and the exercise price of,
this Option.

 

12.          Subject
to Plan. The Option and the Shares granted and issued pursuant to this Agreement have been granted and issued under, and are
subject to the terms of, the Plan. The terms of the Plan are incorporated by reference in this Agreement in their entirety, and
Optionee, by execution of this Agreement, acknowledges having received a copy of the Plan. The provisions of this Agreement shall
be interpreted as to be consistent with the Plan, and any ambiguities in this Agreement shall be interpreted by reference to the
Plan. If any provisions of this Agreement are inconsistent with the terms of the Plan, the terms of the Plan shall prevail.

 

    

     

    

 

13.          Shareholder
Agreements. Upon the exercise of the Option, Optionee shall, at the request of the Company, execute and deliver such voting,
co-sale and other agreements as the Company requests generally of holders of amounts of stock corresponding to that of such Optionee;
and if Optionee fails to execute and deliver any such agreement, such Optionee shall nevertheless hold all stock subject to, and
be bound by, such agreement.

 

14.          Binding
Effect. This Agreement shall be binding upon the heirs, executors, administrators and successors of the parties to this Agreement.

 

15.          Governing
Law. This Agreement and all rights and obligations under this Agreement shall be construed in accordance with the Plan and
governed by the laws of the State of Delaware, without regard to conflicts of laws provisions.

 

16.          Entire
Agreement. This Agreement, the Restrictive Covenants Agreement the Plan set forth the entire agreement and understanding of
the parties to this Agreement with respect to the grant and exercise of this Option and the administration of the Plan and supersede
all prior agreements, arrangements, plans and understandings relating to the grant and exercise of this Option and the administration
of the Plan.

 

17.          Amendment
and Waiver. Other than as provided in the Plan and subject to applicable law, this Agreement may be amended, waived, modified
or canceled only by a written instrument executed by the parties to this Agreement or, in the case of a waiver, by the party waiving
compliance. Notwithstanding the preceding, the Optionee agrees that the Administrator may amend the Plan or this Agreement, to
take effect retroactively or otherwise, as deemed necessary or advisable for the purpose of conforming the Plan or the Agreement
to any present or future law relating to plans of this or similar nature (including, but not limited to, Section 409A of the
Code), and to the administrative regulations and rulings promulgated thereunder.

 

18.          Tax
Consequences. Optionee acknowledges that Optionee may incur tax liability as a result of the purchase or disposition of the
Shares and that if any Shares received upon exercise of the Option are sold within one year of exercise or two years of the Grant
Date, the Option will not be treated as an incentive stock option for tax purposes under the Code. The Company shall not be liable
in the event the Option is for any reason deemed not to be an incentive stock option. In addition, although the Option is intended
to be exempt from Section 409A of the Code, the Company shall not be liable to the Optionee in the event the Option is considered
to be subject to Section 409A, which may subject Optionee to additional taxes, interest, and possible penalties. Optionee
should seek professional tax advice before exercising the Option or disposing of the Shares.

 

19.          Electronic
Delivery and Acceptance. The Company may deliver any documents related to this Agreement by electronic means and request Optionee’s
acceptance of this Agreement by electronic means. Optionee hereby consents to receive all applicable documentation by electronic
delivery and to participate in the Plan through an on-line (and/or voice activated) system established and maintained by the Company
or the Company’s third-party stock plan administrator.

 

[Signature Page Follows]

 

    

     

    

 

The parties hereto have executed this Agreement effective as
of the Grant Date.

 

	 	 	VIREO HEALTH INTERNATIONAL, INC.  
	 	 	 
	 	 	By:	 	/s/ Amber Shimpa	 
	 	 	 	Amber Shimpa
	 	 	 	 
	 	 	Its: Chief Financial Officer  
	 	 	 
	By execution of this Agreement, Optionee acknowledges having 	 	OPTIONEE  
	received a copy of the Plan and agrees to all of the terms and 	 	 
	conditions described in this Agreement and in the Plan	 	 
		 	 	/s/ Kyle Kingsley	 
	 	 	Kyle Kingsley  

 

    

     

    

 

SCHEDULE A

PRE-EXISTING OPTIONS

 

Original Number of Shares: 150,000

Price Per Share: $10.00

Original Grant Date: May 1, 2018

 

Original Number of Shares: 20,000

Price Per Share: $10.00

Original Grant Date: May 1, 2018Exhibit 10.8

 

Execution version

 

AMENDED & RESTATED
EXECUTIVE EMPLOYMENT AGREEMENT

 

This Amended & Restated
Executive Employment Agreement is made as of 9th day of March, 2020, between

 

VIREO HEALTH INTERNATIONAL, INC.

(the “Company”)

 

and

 

BRUCE LINTON

(the “Executive”)

 

RECITALS

 

A.          
The Company and the Executive have an employment relationship pursuant to an employment agreement between the Company and
the Executive dated November 6, 2019 (the “Original Employment Agreement”);

 

B.           
The Company and the Executive and wish to amend the terms of the Original Employment Agreement for their mutual benefit;

 

C.           
The Company and the Executive wish to enter into this Agreement respecting the Executive’s terms and conditions of
employment, including the agreement of the Executive to be bound by the restrictive covenants set out in Article 7 hereof;

 

NOW THEREFORE, in consideration
of the mutual covenants and promises set forth herein and for other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged by the Company and the Executive, the parties hereby covenant and agree as follows:

 

ARTICLE 1 – INTERPRETATION

 

Section 1.1 Definitions.

 

In this Agreement:

 

(1)           
“Affiliate” of a person means any person that directly or indirectly controls, is controlled by, or is
under common control with, that person;

 

(2)           
“Agreement” means this agreement, including any schedules hereto, as amended, supplemented, or modified
in writing from time to time;

 

 (3)            “Board” means the Company’s board of directors;

 

(4)           
“Business” means the business of growing, processing and dispensing medical marijuana in multiple U.S.
states outside of the State of Michigan;

 

     

     

    

 

 (5)            “Change of Control” means any of the following:

 

		(a)	any transaction at any time and by whatever means pursuant to which any
person or any group of two or more persons acting jointly or in concert (other than the Company or any wholly owned subsidiary
of the Company) thereafter acquires the direct or indirect “beneficial ownership” (as defined in the Business Corporations
Act (British Columbia)) of, or acquires the right to exercise control or direction over, securities of the Company representing
50% or more of the then issued and outstanding voting securities of the Company in any manner whatsoever, including, without limitation,
as a result of a Take-Over Bid, an issuance or exchange of securities, an amalgamation of the Company with any other person, an
arrangement, a capital reorganization or any other business combination or reorganization;

 

		(b)	the sale, assignment or other transfer of all or substantially all of the
assets of the Company to a person or any group of two or more persons acting jointly or in concert (other than a wholly-owned subsidiary
of the Company);

 

		(c)	the date which is 10 business days prior to the consummation of a complete
dissolution or liquidation of the Company, except in connection with the distribution of assets of the Company to one or more persons
which were wholly- owned subsidiaries of the Company prior to such event;

 

		(d)	the occurrence of a transaction requiring approval of the Company's security
holders whereby the Company is acquired through consolidation, merger, exchange of securities, purchase of assets, amalgamation,
statutory arrangement or otherwise by any person or any group of two or more persons acting jointly or in concert (other than an
exchange of securities with a wholly-owned subsidiary of the Company);

 

		(e)	the Board passes a resolution to the effect that an event comparable to
an event set forth in this definition has occurred; or

 

		(f)	a majority of the members of the Board are replaced during any twelve-month
period by directors whose appointment or election is not endorsed by a majority of the Board before the date of appointment or
election;

 

(6)          
“Company Works” means any works of authorship, inventions, intellectual property, materials, documents
or other work product that the Executive creates, invents, designs, develops, contributes to or improves, either alone or jointly
with others, at any time during Executive’s employment by the Company and within the scope of such employment and/or with
the use of the Confidential Information or other resources of the Company and/or its Affiliates.

 

(7)           “Confidential
Information” means information disclosed or readily accessible to the Executive or acquired by the Executive as a
result of the Executive’s employment with the Company and which is not in the public domain or otherwise required to be
publicly disclosed by applicable law and includes, but is not limited to, information relating to the Company’s or any
of its Affiliates’ current, future or proposed products/services or development of new or improved products/services,
marketing strategies, sales or business plans, the names and information about the Company’s past, present and
prospective customers and clients, technical data, records, reports, presentation materials, interpretations, forecasts, test
results, formulae, projects, research data, personnel data, compensation arrangements, budgets, financial statements, and any
information received by the Company from third parties pursuant to an obligation of confidentiality;

 

     

     

    

 

(8)          
“Date of Termination” means the Executive’s last active day of employment with the Company without
regard to any notice of termination or pay in lieu thereof, deemed or notional notice period, or period during which the Executive
receives pay in lieu of notice, termination pay, severance payments, or salary continuance, whether pursuant to statute, this Agreement,
common law or otherwise;

 

(9)          
“Triggering Transaction” means: (a) a Change of Control or (b) a debt, equity or hybrid financing transaction,
regardless of whether secured or unsecured, whether publicly or privately sourced, and whether the proceeds are paid to the Company
or any subsidiary of the Company for aggregate gross proceeds of at least $8 million. A Triggering Transaction can be comprised
of a single transaction or multiple, related transactions.

 

(10)        
“Just Cause” means any one or more of the following committed by the Executive: willful misconduct in
the performance of the Executive’s duties or other intentional and material violation of the Company’s policies and
procedures; breach of any fiduciary duty the Executive owes to the Company; conviction of the Executive of any criminal offence
involving an act of dishonesty, deceit or fraud, or the commission of acts that could reasonably be expected to result in such
a conviction; any neglect of duty, wilful failure to perform the essential duties of the Executive’s position in a reasonably
satisfactory manner (other than any such neglect or failure resulting from disability), or other material breach of any material
provision of this Agreement by the Executive which is not cured after 30 days’ written notice by the Company to the Executive;
or any other act or omission that amounts to just cause for summary dismissal at common law;

 

(11)        
“Take-Over Bid” means a take-over bid as defined in National Instrument 62-104 – Take- Over
Bids and Issuer Bids;

 

 (12)         “Territory” means the United States of America; and

 

(13)        
“Total Disability” means any physical or mental incapacity, disease or affliction of the Executive (as
determined by a legally qualified medical practitioner) which has prevented or which will prevent the Executive from performing
the essential duties of the Executive’s position (taking into account accommodation by the Company in accordance with applicable
human rights legislation) for a continuous period of six (6) months or any cumulative period of 180 days in any 12 consecutive
month period.

 

ARTICLE 2 –
TERM

 

This
Agreement, and the Executive’s employment with the Company hereunder, shall commence effective November 7, 2019 (the “Effective
Date”) and will continue until the three (3) year
anniversary of the Effective Date (the “End Date”), unless terminated earlier in accordance with Article 6
of this Agreement.

 

     

     

    

 

ARTICLE 3 –
EMPLOYMENT AND POSITION

 

Section 3.1 Position.

 

Subject
to the terms and conditions set out in this Agreement, the Company hereby agrees to employ the Executive, and the Executive hereby
agrees to serve the Company, in the position of Executive Chairman.

 

Section 3.2 Travel.

 

The
Executive acknowledges that the duties of the Executive’s position may require some travel within and outside Canada.

 

Section 3.3 Representations
and Warranties of Executive.

 

The
Executive represents and warrants to the Company that the execution and performance of this Agreement will not result in or constitute
a default, breach, or violation, or an event that, with notice or lapse of time or both, would be a default, breach, or violation,
of any understanding, agreement or commitment, written or oral, express or implied, to which the Executive is a party, provided
that during the period commencing as of the date hereof and ending on the earlier of (i) July 3, 2021; and (ii) the termination
of this Agreement in accordance with its terms, neither the Company nor any of its Affiliates, alone or in partnership or association
with any other person, corporation, partnership, business, or entity, shall be engaged in the growing, extraction, and sales of
cannabis and cannabis related products within Canada.

 

Section 3.4 Representations
and Warranties of the Company.

 

The Company
represents and warrants to the Executive that neither the Company nor any of its Affiliates, alone or in partnership or association
with any other person, corporation, partnership, business, or entity, is engaged in the growing, extraction, and sales of cannabis
and cannabis related products within Canada.

 

Section 3.5 Company’s
Covenant.

 

The
Company covenants and agrees that during the period commencing as of the date hereof and ending on the earlier of (i) July 3, 2021;
and (ii) the termination of this Agreement in accordance with its terms, neither the Company nor any of its Affiliates, alone or
in partnership or association with any other person, corporation, partnership, business, or entity, shall be engaged in the growing,
extraction, and sales of cannabis and cannabis related products within Canada.

 

     

     

    

 

ARTICLE 4 – DUTIES

 

Section 4.1 Not
Full-Time Employment; Outside Activities.

 

The
Executive’s position with the Company does not constitute the Executive’s full-time employment. Throughout the
duration of the Executive’s employment, the Executive shall devote reasonable time and attention to the business and
affairs of the Company, acting in the best interests of the Company. Notwithstanding the foregoing, the parties mutually
agree that the Executive shall be permitted to engage in other directorship, consulting or other business activity
(collectively, the “Outside Activities”), subject to compliance with applicable law and so long as such
activities do not interfere with the Executive’s ability to fulfill his obligations to the Company under this Agreement
or place the Executive into any conflict of interest in respect of his duties hereunder. In the event of an actual or
potential conflict of interest vis-à-vis the Outside Activities and the Executive’s duties hereunder (a
 “Conflict of Interest”), the Executive shall immediately upon becoming aware of such Conflict of Interest
recuse himself from all discussions, decisions and actions taken by or on behalf of the Company, on one hand, and the Outside
Activities, on the other hand, which relate to the Conflict of Interest. For greater certainty, a Conflict of Interest
includes any situation, whether actual or perceived, where the Executive’s ability to fulfill his obligations to the
Company under this Agreement (including without limitation his fiduciary duty to act honestly, in good faith and with a view
to the best interests of the Company) could reasonably be expected to be compromised.

 

Section
4.2 Duties; Reporting.

 

The
Executive shall report to and be subject to the direction of the Board. The Executive’s role will initially consist primarily
of leading the Company’s strategic and capital markets activities, and shall include but not be limited to the following:

 

		(a)	The Executive shall use reasonable efforts to mention the Company favorably
to reputable, broadly distributed media;

 

		(b)	The Executive shall use reasonable efforts to attend conferences, analyst/investor
calls and earnings calls as reasonably requested by the Company;

 

		(c)	The Executive shall use reasonable efforts to assist in all of the Company’s
capital raises and other financing activities; and

 

		(d)	The Executive shall use reasonable efforts to facilitate the Company entering
into beneficial relationships with domestic and international investors, lenders, customers, suppliers, joint venture partners,
co-marketing partners and co- branding partners.

 

The
Executive shall have other duties and responsibilities consistent with the Executive’s position as may reasonably be assigned
to the Executive by the Board from time to time. The Executive shall comply with all applicable laws in the performance of the
Executive’s duties. For greater clarity, the Executive shall not be obligated to carry on any of the activities set out in
this Section 4.2 if such activities would violate applicable laws, “quiet period” policies or any other governance
policies of the Company that are applicable to the Executive. Except for the Executive’s duties as a member of the Board,
the Executive’s duties and responsibilities shall be undertaken at the Executive’s reasonable discretion during the
period commencing on December 15 and ending on January 15 (the “Holiday Period”) of any particular year during
the term of this Agreement, provided that if the Company is actively engaged in capital raising, other financing activity or M&A
activity during the Holiday Period, the Executive shall use all reasonable efforts to assist the Company in such capital raising,
other financing activity or M&A activity.

 

     

     

    

 

ARTICLE 5 – COMPENSATION
AND BENEFITS

 

Section 5.1 Base
Salary.

 

The
Executive’s base salary shall be US$250,000 per year (the “Base Salary”). During the period commencing
on the Effective Date and ending on the date of closing a Triggering Transaction (the “Salary Trigger Date”),
the Company shall pay the Executive only that portion of the Executive’s Base Salary that is equal to the minimum wage rate
required by the Employment Standards Act, 2000, as amended (the “Act”). On the Salary Trigger
Date, all accrued, unpaid Base Salary due to the Executive shall promptly, and in no event later than 5 business days following
closing of such Triggering Transaction, be paid to the Executive and for each successive year that the Executive is employed with
the Company following the Salary Trigger Date, the Executive shall be paid the full amount of the Base Salary. All payments to
the Executive of Base Salary shall be made less applicable deductions and withholdings, in accordance with the Company’s
standard payroll practices and prorated in any year where the Executive is not actively employed with the Company for the full
calendar year. The Company has the sole discretion to increase the Executive’s Base Salary annually or on some other basis,
based on personal and corporate achievements and the overall financial performance of the Company.

 

Section 5.2 [Intentionally
deleted.]

 

[Intentionally deleted.]

 

Section 5.3 Incentive
Warrants.

 

The
Company approved the grant to the Executive of an aggregate of 15,000,000 non- transferrable share purchase warrants (the “Incentive
Warrants”) on November 6, 2019, with each Incentive Warrant entitling the Executive to acquire one subordinate voting
share of the Company (a “Share”) at the following exercise prices:

 

		(a)	10,000,000 Incentive Warrants at an exercise price of US$1.02 per Share (the
 “First Tranche Incentive Warrants”);

 

		(b)	2,500,000 Incentive Warrants at an exercise price of US$3.81 per Share (the
 “Second Tranche Incentive Warrants”); and

 

		(c)	2,500,000 Incentive Warrants at an exercise price of US$5.86 per Share (the
 “Third Tranche Incentive Warrants”).

 

The
Incentive Warrants have a term expiring on November 6, 2024 (the “Incentive Warrant Expiry Date”) and vest as
follows: (i) 5,000,000 First Tranche Incentive Warrants, 1,250,000 Second Tranche Incentive Warrants and 1,250,000 Third Tranche
Incentive Warrants vest on November 6, 2020; and (ii) 5,000,000 First Tranche Incentive Warrants, 1,250,000 Second Tranche Incentive
Warrants and 1,250,000 Third Tranche Incentive Warrants vest on November 6, 2021, subject to the provisions of this Section 5.3.

 

During
the term of the Incentive Warrants, should the Executive’s employment be terminated pursuant to Section 6.1(3) or
Section 6.1(5) (i) any Incentive Warrants which have then vested and which have not been duly and properly exercised prior to
such time will have their term and the Incentive Warrant Expiry Date accelerated to the date that is one year from the Date
of Termination (the “Accelerated Expiry Date”) and such vested Incentive Warrants will remain exercisable
until the Accelerated Expiry Date and any Incentive Warrants not so exercised by the Accelerated Expiry Date will cease to be
exercisable and will expire and become null and void and (ii) any Incentive Warrants which have not then vested will
immediately cease to be exercisable and will expire and become null and void as of the Date of Termination.

 

     

     

    

 

During
the term of the Incentive Warrants, should the Executive cease to be an employee of the Company for any reason, other than as a
result of a termination pursuant to Section 6.1(3) or Section 6.1(5), the Incentive Warrants which have not then vested will immediately
prior to the Date of Termination be deemed to become vested and such Incentive Warrants will remain exercisable until the Accelerated
Expiry Date.

 

In
the event of a Change of Control during the term of the Incentive Warrants, the Incentive Warrants which have not then vested will
immediately prior to the Change of Control be deemed to become vested and such Incentive Warrants will remain exercisable until
the Incentive Warrant Expiry Date.

 

Section
5.4 Exemption from Prospectus Requirements.

 

On
or prior to the issuance of the Incentive Warrants, the Executive executed and delivered a Form 45-106F12 – Risk Acknowledgement
Form for Family, Friends and Business Associates in the form attached as Schedule D.

 

The
Executive hereby represents, warrants to, and covenants with, the Company (which representations, warranties and covenants will
survive the issuance of the Incentive Warrants) as follows:

 

		a)	no prospectus has been filed by the Company with any securities commission
or similar authority, in connection with the issuance of the Incentive Warrants, and the issuance of the Incentive Warrants is
subject to such issue being exempt from the prospectus/registration requirements under applicable securities laws and accordingly:

 

		i.	the Executive is restricted from using certain of the civil remedies available
under such legislation;

 

		ii.	the Executive may not receive information that might otherwise be required
to be provided to it under such legislation; and

 

		iii.	the Company is relieved from certain obligations that would otherwise apply
under such legislation;

 

		b)	the Executive has been advised to consult its own legal advisors with respect
to the merits and risks of an investment in the Incentive Warrants and with respect to applicable resale restrictions and the Executive
is solely responsible (and the Company is in no way responsible) for compliance with applicable resale restrictions;

 

		c)	to the knowledge of the Executive, the issue of the Incentive Warrants was
not accompanied by any advertisement;

 

     

     

    

 

		d)	the Executive acknowledges and consents to the collection and retention
by the Company of certain information, including personal information, regarding the Executive and the issuance of the Incentive
Warrants. The Executive acknowledges and agrees that this information will be retained on the warrant register of the Company which
may be available for inspection by the public. The Executive further consents and agrees to the release of this information to
the securities regulatory authorities and any securities exchange the Company may become listed on, as required by law, and regulatory
and exchange policies;

 

		e)	the Executive is sophisticated in financial investments, has had access
to and has received all such information concerning the Company that the Executive has considered necessary in connection with
the issuance of the Incentive Warrants;

 

		f)	no agency, governmental authority, regulatory body, stock exchange or other
entity has made any finding or determination as to the merit for investment of, nor have any such agencies or governmental authorities
made any recommendation or endorsement with respect to, the Incentive Warrants;

 

		g)	the Executive acknowledges that the Company may complete additional financings
in the future which may have a dilutive effect on existing shareholders at such time, including the Executive;

 

		h)	to the knowledge of the Executive, no commission or finder’s fee
was paid to any director, officer, founder, or control person of an issuer or an affiliate of the Company in connection with the
issue of the Incentive Warrants; and

 

		i)	the Company will rely on the representations and warranties made herein
or otherwise provided by the Executive to the Company in completing the issue of the Incentive Warrants to the Executive.

 

The Company hereby represents,
warrants to, and covenants with, the Executive (which representations, warranties and covenants will survive the issuance of the
Incentive Warrants) as follows:

 

		a)	the Company has the power and authority to create, issue and deliver the
Incentive Warrants;

 

		b)	the Shares will, at the time of exercise of the Incentive Warrants, be
duly allotted, validly issued, fully paid and non-assessable and will be free of all liens, charges and encumbrances and the Company
will reserve sufficient shares in the treasury of the Company to enable it to issue the Shares;

 

		c)	the Company has complied, or will comply, with all applicable securities
laws in connection with the issuance of the Incentive Warrants;

 

		d)	the Company has complied and will comply fully with the requirements of
all applicable corporate and securities laws and administrative policies and directions, in relation to the issuance of the Incentive
Warrants and the trading of its securities;

 

     

     

    

 

		e)	the issue and sale of the Incentive Warrants by the Company does not and
will not conflict with, and do not and will not result in a breach of, or constitute a default under (A) any
law, statute, rule or regulation applicable to the Company including, without limitation, the applicable securities laws; (B)
the constating documents, articles or resolutions of the Company which are in effect at the date hereof; (C) any agreement,
debt instrument, mortgage, note, indenture, instrument, lease or other document to which the Company is a party or by which
it is bound; or (D) any judgment, decree or order binding the Company or the property or assets of the Company; and

 

		j)	the Company shall not take any action which would be
reasonably expected to result in the delisting or suspension of the Shares on or from the Canadian Securities Exchange or on or
from any stock exchange, market or trading or quotation facility on which its common shares are listed or quoted and the Company
shall comply, in all material respects, with the rules and regulations thereof.

 

Section 5.5 Loan.

 

Provided
that (i) the Company receives binding commitments from subscribers for a Triggering Transaction on or before March 7, 2020, which
Triggering Transaction is thereafter completed on or before March 9, 2020; and (ii) in connection with the Triggering Transaction,
the Executive subscribes, directly or indirectly, for equity securities of the Company in an amount no less than $1,000,000 and
delivers the full amount due under the subscription agreement on or before March 9, 2020, the Company shall advance to the Executive,
in one or more tranches, an amount equal to US$10,200,000 by way of a loan (the “Loan”) pursuant to the terms
of the promissory note (the “Note”) attached hereto as Schedule B. The Company shall make the Loan effective
as of March 9, 2020, provided that (i) the Company receives binding commitments from subscribers for a Triggering Transaction on
or before March 7, 2020, which Triggering Transaction is thereafter completed on or before March 9, 2020; and (ii) in connection
with the Triggering Transaction, the Executive subscribes, directly or indirectly, for equity securities of the Company in an amount
no less than $1,000,000 and delivers the full amount due under the subscription agreement on or before March 9, 2020. The Executive
agrees to draw down on the Loan, in whole or in part, solely to exercise the First Tranche Incentive Warrants that at the time
of exercise are beneficially owned by the Executive.

 

Section 5.6 Insider Lock-Up Agreements.

 

On
or prior to the Effective Date, the Company obtained a lock-up agreement, in a form acceptable to the Executive, acting reasonably,
from each of the directors and officers of the Company and its Affiliates (collectively, the “Insiders”) whereby
the Insiders agree not to sell, transfer, pledge or otherwise dispose of any Shares of the Company or securities exchangeable or
convertible into Shares of the Company until November 6, 2020.

 

Section 5.7 Service Bonus.

 

Provided
that (i) the Company receives binding commitments from subscribers for a Triggering Transaction on or before March 7, 2020,
which Triggering Transaction is thereafter completed on or before March 9, 2020; and (ii) the Executive subscribes, directly
or indirectly, for equity securities of the Company in an amount no less than $1,000,000 in connection with the Triggering
Transaction and delivers the full amount due under the subscription agreement on or before March 9, 2020, the Executive shall
be eligible to receive one or more bonuses (each a “Service Bonus”) for services performed on behalf of
the Company during the term of this Agreement which, in the aggregate, shall be equal to the total amount of Eligible Draw
Downs made by the Executive. Each Service Bonus shall be earned by and payable to the Executive on the one-year anniversary
of the date that the Executive makes an Eligible Draw Down.

 

     

     

    

 

For
the purposes of this Section 5.7, an “Eligible Draw Down” means a draw down on the Loan by the Executive in order to
exercise First Tranche Incentive Warrants on a date when the Company’s market capitalization, calculated on an as-converted
subordinate voting share basis based on the volume weighted average trading price of the subordinate voting shares during the 20-day
period immediately preceding the date of exercise of such Incentive Warrants, equals or exceeds $275,831,882.50 (being two times
the Company’s market capitalization, calculated on an as-converted subordinate voting share basis based on the closing price
of the subordinate voting shares on the close of trading on February 14, 2020).

 

Notwithstanding
the immediately preceding paragraph, upon the occurrence of a Change of Control, an Eligible Draw Down shall mean any draw down
on the Loan by the Executive in order to exercise Incentive Warrants irrespective of the Company’s market capitalization
on the date of such draw down.

 

For illustrative purposes,
if the Executive makes an Eligible Draw Down in the amount of $100,000 on July 1, 2020, he shall be entitled to receive a
Service Bonus of $100,000, less applicable deductions and withholdings, on July 1, 2021. In the event that the Executive does
not make any Eligible Draw Downs, the Executive shall not be entitled to receive a Service Bonus.

 

Section 5.8 Benefits.

 

The
Executive shall be eligible to participate in the Company’s group insured benefit plan, subject to the terms and conditions
of such plan and applicable policies, as may be amended from time to time without advance notice. The Company reserves the right
to change its benefit plan or carrier in its sole and absolute discretion.

 

Section 5.9 Vacation.

 

The
Executive shall be entitled to four (4) weeks of vacation per calendar year, such vacation to extend for such periods and to be
taken at such intervals as shall be appropriate and consistent with the proper performance of the Executive’s duties and
as agreed upon between the Executive and the Company. Vacation must be used every year and cannot be carried-forward or paid out
at year end (except as required in order to comply with applicable employment standards legislation).

 

Section 5.10 Reimbursement
of Expenses.

 

The
Executive will be eligible for reimbursement of reasonable and necessary business and travel expenses actually incurred by the
Executive directly in connection with the business affairs of the Company and the performance of the Executive’s duties hereunder,
upon presentation of proper receipts or other proof of expenditure acceptable to the Company, in accordance with the Company’s
expense reimbursement policy. The Executive shall comply with such reasonable limitations and reporting requirements with respect
to such expenses as the Company may establish from time to time.

 

     

     

    

 

Section 5.11 No
Other Benefits.

 

The Executive
is not entitled to any other payment, benefit, perquisite, allowance or entitlement other than as specifically set out in this
Agreement, or as mandated by applicable laws, or as otherwise approved in writing and signed by the Company and the Executive.

 

ARTICLE 6 –
TERMINATION OF EMPLOYMENT

 

Section 6.1 Termination.

 

The
Executive’s employment will automatically terminate on the End Date without any further obligation from the Company to the
Executive, whether on account of notice of termination, payment in lieu of notice of termination, severance or termination pay,
benefits or any damages whatsoever, except as may be required by the Act; provided, however, that the Executive’s
employment may be terminated earlier as follows:

 

(1)          
Death. This Agreement and the Executive’s employment shall automatically terminate upon the death of the Executive.

 

(2)           Total
Disability. The Company may terminate this Agreement and the Executive’s employment at any time as a result of Total
Disability in accordance with Section 6.4.

 

(3)           Just
Cause. The Company may terminate this Agreement and the Executive’s employment at any time for Just Cause in accordance
with Section 6.3.

 

(4)           Without
Just Cause. The Company may terminate this Agreement and the Executive’s employment at any time without Just Cause,
for any reason or no reason whatsoever, by providing written notice to the Executive specifying the effective Date of Termination
(which may be forthwith). In such event, the Company shall provide, and the Executive shall be entitled to receive the notice,
payments, benefits and/or entitlements set out in Section 6.5 below.

 

(5)           Resignation.
The Executive may terminate this Agreement and the Executive’s employment at any time by providing three (3) months’
advance written notice to the Company. The Company may elect to waive all or part of such notice, to the extent permitted by applicable
employment standards legislation.

 

(6)           Material
Breach. The Executive may terminate this Agreement and the Executive’s employment hereunder upon a material breach by
the Company of a fundamental term or condition of this Agreement (“Material Breach”) if, upon, giving 30 days’
written notice to the Company of the Material Breach, the Company does not rectify the Material Breach within 30 days of receiving
notice from the Executive. If the Company does not rectify the Material Breach within the 30-day period, the Company shall provide,
and the Executive shall be entitled to receive the notice, payments, benefits and/or entitlements set out in Section 6.5 below.

 

     

     

    

 

Section 6.2 Termination
by Reason of Death or Resignation.

 

 

If
this Agreement and the Executive’s employment is terminated pursuant to Sections 6.1(1) or 6.1(5) above, then the
Company shall pay to the Executive (or, in the case of the Executive’s death, to the Executive’s estate) an
amount equal to the base salary, vacation pay and any other accrued unpaid compensation fully earned by and payable to the
Executive up to the Date of Termination, and the Executive shall have no entitlement to any further notice of termination,
payment in lieu of notice of termination, severance or termination pay, benefits or any damages whatsoever. Participation in
all equity or profit participation plans (if any) terminates immediately upon the Date of Termination and the Executive shall
not be entitled to any additional bonus or incentive award, pro rata or otherwise.

 

Section
6.3 Termination by Reason of Just Cause.

 

If this
Agreement and the Executive’s employment is terminated pursuant to Section 6.1(3) above, then the Company shall pay to the
Executive an amount equal to the base salary, vacation pay and any other accrued unpaid compensation fully earned by and payable
to the Executive up to the Date of Termination, and the Executive shall have no entitlement to any further notice of termination,
payment in lieu of notice of termination, severance or termination pay, benefits or any damages whatsoever, except as may be required
by the Act. Participation in all equity or profit participation plans (if any) terminates immediately upon the Date of Termination
and the Executive shall not be entitled to any additional bonus or incentive award, pro rata or otherwise, except as required
by the Act.

 

Section
6.4 Termination by Reason of Total Disability.

 

If this
Agreement and the Executive’s employment is terminated pursuant to Section 6.1(2) above, then the Company shall pay to the
Executive an amount equal to the base salary, vacation pay and any other accrued unpaid compensation earned by and payable to the
Executive up to the Date of Termination, and the Company shall provide to the Executive only the minimum payment in lieu of notice
of termination, severance pay, benefits and other entitlements required by the Act (if any).

 

Section
6.5 Termination Without Just Cause or for Material Breach.

 

If this
Agreement and the Executive’s employment is terminated by the Company without Just Cause pursuant to Section 6.1(4) above
or by the Executive for Material Breach pursuant to Section 6.1(6), then the following provisions shall apply:

 

(1)           The
Company shall pay to the Executive an amount equal to the base salary, vacation pay and any other accrued unpaid compensation
fully earned by and payable to the Executive up to the Date of Termination.

 

	(2)	The Company shall provide to the Executive the greatest of:

 

		(a)	the minimum notice of termination, or payment in lieu of notice of termination,
severance pay, benefits continuation and other minimum entitlements required by the Act; or

 

		(b)	notice of termination, or base salary and benefits continuation in lieu
thereof, equivalent to twelve months (provided however that if any benefit cannot be continued, due to carrier restrictions, the
Company will provide the Executive with a sum equal to its portion of the benefit premiums for such benefits) (such period of time
being the “Severance Benefit Period”); provided, however,
that this Section 6.5(2) will be subject to any requirement under the Act to pay to the Executive the portion of such payments
that constitutes the Executive’s minimum termination and severance pay entitlement in a lump sum within a prescribed time
period under such legislation.

 

     

     

    

 

Section 6.6 All
Inclusive.

 

The
Executive acknowledges and agrees that provision of the entitlements set out in this Article 6 shall constitute full and final
satisfaction of any claim which the Executive might have arising from or relating to the termination of the Executive’s employment,
whether such claim arises under statute, contract, common law or otherwise. In the event that greater entitlements are required
to be given by the Company to the Executive pursuant to the Act, Article 6 shall be construed as providing for the provision of
such greater entitlements (and no more). For the avoidance of doubt, if the Company provides base salary in lieu of notice to the
Executive pursuant to Section 6.5(2)(b), such base salary in lieu of notice shall be inclusive of severance pay under the Act,
however, if the Company exercises its right to provide notice instead of pay in lieu thereof, the Executive will also be provided
with any termination and severance pay still owing to the Executive pursuant to the Act in a lump sum within a prescribed time
period under such legislation.

 

Section 6.7 Release.

 

Payments
to the Executive upon termination in accordance with this Agreement by the Company, assuming such payments exceed the Executive’s
minimum entitlements pursuant to Act, will be dependent upon the Executive signing a mutual full and final release, acknowledging
that the payment is inclusive of, and satisfies all of the Executive’s entitlements pursuant to applicable legislation, contract,
common law and equity, and will release the Company (including all current and former parent, subsidiary, related and affiliated
corporations and divisions and all of its and their current and former officers, directors, agents, employees, successors and assigns)
from any and all actions, causes of actions, proceedings, claims, demands or complaints including, without limitation, any claims
in respect of the Executive’s hiring by, employment with and termination of employment with the Company and any human rights
claims. However, and in any event, the Executive shall not be provided with less than the Executive’s minimum entitlements
pursuant to the Act. Accordingly, without limitation, if the Executive refuses to sign a mutual full and final release, the Executive
will be entitled to only such minimum notice of termination, or payment in lieu of notice of termination, severance pay, benefits
continuation and other minimum entitlements required by the Act.

 

Section 6.8 Return
of Property.

 

All equipment,
keys, pass cards, credit cards, software, material, data, written correspondence, memoranda, communication, reports, or other documents
or property pertaining to the Business of the Company or containing Confidential Information, used or produced by the Executive
in connection with the Executive’s employment, or in the Executive’s possession or under the Executive’s control,
shall at all times remain the exclusive property of the Company. The Executive shall return all property of the Company in the
Executive’s possession or under the Executive’s control in good condition, and all documents or property containing
Confidential Information (without retaining any copy, electronic or otherwise), forthwith upon any request by the Company or upon
any termination of this Agreement and of the Executive’s employment (whether voluntary or involuntary, lawful or unlawful,
and with or without Just Cause).

 

     

     

    

 

Section 6.9 Change
of Position Border Services Status Change.

 

(1)           Following
a Border Services Status Change during the term of this Agreement, the Executive shall resign from his role as Executive Chairman,
and continue in the Company’s employment in an alternate position that does not require the Executive to enter the United
States (an “Alternate Position”). In this Alternate Position, the terms of this Agreement will remain the same
and continue to apply to this employment relationship, including the Executive’s remuneration and benefits.

 

(2)           For
the purposes of this Agreement, the term “Border Services Status Change” means the Executive is refused entry on more
than one occasion into the United States after the Effective Date.

 

ARTICLE 7 –
CONFIDENTIALITY & RESTRICTIVE COVENANTS

 

Section 7.1 Protection
of Confidential Information.

 

While
employed by the Company and following the termination of this Agreement and the Executive’s employment (whether voluntary
or involuntary, lawful or unlawful, and with or without Just Cause), the Executive shall not, directly or indirectly, in any way
use or disclose to any person any Confidential Information except as provided for herein. The Executive agrees and acknowledges
that the Confidential Information of the Company is the exclusive property of the Company to be used exclusively by the Executive
to perform the Executive’s duties and fulfil the Executive’s obligations to the Company and not for any other reason
or purpose. Therefore, the Executive agrees to hold all such Confidential Information in trust for the Company, and the Executive
further confirms and acknowledges the Executive’s fiduciary duty to use the Executive’s best efforts to protect the
Confidential Information, not to misuse such information, and to protect such Confidential Information from any misuse, misappropriation,
harm or interference by others in any manner whatsoever. The Executive agrees to protect the Confidential Information regardless
of whether the information was disclosed in verbal, written, electronic, digital, visual or other form, and the Executive hereby
agrees to give notice immediately to the Company of any unauthorized use or disclosure of Confidential Information of which the
Executive becomes aware. The Executive further agrees to assist the Company in remedying any such unauthorized use or disclosure
of Confidential Information. In the event that the Executive is required to disclose to third parties any Confidential Information
or any memoranda, opinions, judgments or recommendations developed from the Confidential Information, by law, valid court order
or subpoena, the Executive will, prior to disclosing such Confidential Information, provide the Company with prompt written notice
of such request(s) or requirement(s) so that the Company may seek appropriate legal protection or waive compliance with the provisions
of this Agreement. The Executive will not oppose action by, and will cooperate with, the Company to obtain legal protection or
other reliable assurance that confidential treatment will be accorded the Confidential Information.

 

Section 7.2 Corporate
Opportunities.

 

Subject
to the Executive’s right to participate in the Outside Activities in accordance with Section 4.1 hereof, and subject to
any confidentiality obligations owed to such Outside Activities, any business opportunities related to the Business of the
Company or any of its Affiliates which would be beneficial to the Business of the Company or any of its Affiliates and which
become known to the Executive during the Executive’s employment hereunder shall be fully disclosed and made available
to the Company and shall not be appropriated by the Executive under any circumstance without the prior written consent of the
Company.

 

     

     

    

 

Section
7.3 Intellectual Property Rights.

 

The Executive acknowledges and agrees that:

 

(1)           All
Company Works relating to or connected with any of the matters which have been, are or may become the subject of the Company’s
Business or in which the Company has been, is or may become interested, are the exclusive property of the Company. The Executive
hereby unconditionally and irrevocably waives any and all moral rights and “droit morale” in the Company Works.

 

(2)           The
Executive shall promptly and fully disclose all Company Works to the Company and hereby irrevocably and unconditionally assigns,
transfers and conveys, and agrees to assign, transfer and convey in the future, to the maximum extent permitted by applicable
law, all proprietary and intellectual property rights in the Company Works (including but not limited to rights under patent,
industrial property, copyright, trademark, trade secret, unfair competition and related laws) to the Company, to the extent ownership
of any such rights does not vest originally in the Company.

 

(3)           The
Executive shall take all requested actions and execute all requested documents (including any licenses or assignments required
by a government contract) at the Company’s expense (but without further remuneration) to assist the Company in validating,
maintaining, protecting, enforcing, perfecting, recording, patenting or registering any of the Company’s rights in the Company
Works. If the Company is unable for any reason to secure the Executive’s signature on any document for this purpose, then
the Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Executive’s
agent and attorney in fact, to act for and on the Executive’s behalf and stead to execute any documents and to do all other
lawfully permitted acts in connection with the foregoing.

 

(4)           The
Executive shall not improperly use for the benefit of, bring to any premises of, divulge, disclose, communicate, reveal, transfer
or provide access to, or share with the Company any confidential, proprietary or non-public information or intellectual property
relating to a former employer or other third party without the prior written permission of such third party.

 

(5)           The
Executive shall comply with all relevant policies and guidelines of the Company or its Affiliates regarding the protection of
Confidential Information and intellectual property and potential conflicts of interest, provided same are consistent with the
terms of this Agreement. The Executive acknowledges that the Company or its Affiliates may amend any such policies and guidelines
from time to time, and that the Executive remains at all times bound by their most current version.

 

(6)           Confidential
Information, Company Works and intellectual property, as defined and/or described herein shall not include any publicly
available information or any information that Executive had or owned prior to the Effective Date or which was disclosed to
the Executive by a third party who, to the knowledge of the Executive, did not owe a duty of confidentiality to the Company,
or which was developed by the Executive prior to the Effective Date or which was developed by the Executive on the
Executive’s own time with the Executive’s own tools and/or materials as set forth in Schedule C. The Executive
acknowledges and agrees that except for those items listed in Schedule C, any and all such information, works, and/or
intellectual property are those of the Company.

 

     

     

    

 

(7)           In
respect of the Company Works, the Executive irrevocably and unconditionally consents to the fullest extent permitted by law (either
present or future) to the Company, its licensees, contractors, assignees and successors and their licensees, and any other persons
authorised by any of them:

 

		(a)	using, disclosing, reproducing, copying, adapting, publishing, performing,
exhibiting, communicating or transmitting any of the Company Works or any adaptation of any of them (or any part of any of the
Company Works or of any such adaptation) anywhere in the world, in whatever form and in whatever circumstances the Company, its
licensees, contractors, assignees and successors and their licensees, and any other person authorised by any of them, thinks fit,
including the making of any distortions, additions or alterations to any of the Company Works, or mutilating or destroying any
of the Company Works, or any adaptation of any of them (or any part of any of the Company Works or of any such adaptation) as so
used, disclosed, reproduced, copied, adapted, published, performed, exhibited, communicated or transmitted; and

 

		(b)	using, disclosing, reproducing, copying, adapting, publishing, performing,
exhibiting, communicating or transmitting any of the Company Works or any adaptation of any of them (or any part of any of the
Company Works or of any such adaptation) anywhere in the world without making any identification of the author in relation to any
of them.

 

(8)           Upon
cessation of active service with the Company, or at any time upon the Company’s request, the Executive shall return (without
retaining any copies, electronic or otherwise) all Company Works created by the Executive (either solely or jointly with others)
during the Executive’s employment with the Company. Without limiting the foregoing, the Executive agrees that the Executive
does not and will not have the right to publish or otherwise utilize the Company Works on the Executive’s own behalf or
on behalf of any third party.

 

Section
7.4 Non-Competition.

 

Subject
to the Executive’s right to participate in the Outside Activities in accordance with Section 4.1 hereof, the Executive covenants
that the Executive will not (without prior written consent of the Company) at any time during the period commencing as of the Effective
Date and ending on the last day of the Severance Benefit Period, directly or indirectly, anywhere within the Territory, either
individually or in partnership, jointly or in conjunction with any other person, firm, association, syndicate, company or corporation,
whether as agent, employee, consultant, or in any manner whatsoever, engage in, carry on or otherwise be concerned with, any United
States multistate operator in the cannabis industry that is competitive with the Business. For greater certainty, the Executive’s
involvement with: (i) a single state operator in the cannabis industry in the State of Michigan that holds minority interests in
other entities; or (ii) any Outside Activity that may become competitive with the Business following the date of the Executive’s
involvement in such Outside Activity, shall not violate the restrictive covenants contained in this Section 7.4.

 

     

     

    

 

Section 7.5 Non-Solicitation.

 

The Executive
covenants that the Executive will not (without prior written consent of the Company) during the period commencing as of the Effective
Date and ending on the last day of the Severance Benefit Period, directly or indirectly, either individually or in partnership,
jointly or in conjunction with any other person, firm, association, syndicate, company or corporation, whether as agent, employee,
consultant, or in any manner whatsoever:

 

(1)           solicit
or entice away, or endeavour to solicit or entice away from the Company, employ, or otherwise engage (as an employee, independent
contractor, or otherwise) any person whom the Executive had contact with or Confidential Information about during the Executive’s
employment with the Company (in connection with such employment), and who is employed by the Company or engaged as a contractor
or consultant by the Company as at the Date of Termination or who was so employed or engaged within the twelve (12) month period
preceding such date; or

 

(2)            for
any purpose competitive with the Business, canvass, solicit or approach for orders, or cause to be canvassed or solicited or approached
for orders from any person or entity whom the Executive had contact with or Confidential Information about during the Executive’s
employment with the Company (in connection with such employment), and who is or which is a customer, client, supplier, licensee
or business relation of the Company as at the Date of Termination or within the six-month period preceding such date; or

 

(3)            induce
or attempt to induce any customer, client, supplier, licensee or business relationship of the Company whom the Executive had contact
with or Confidential Information about during the Executive’s employment with the Company (in connection with such employment),
to cease doing business with the Company; or

 

(4)           at
any time following the date the Executive ceases to be an employee of the Company (regardless of whether such termination is voluntary
or involuntary, lawful or unlawful, and with or without Just Cause), disparage or denigrate the Company or its Affiliates or their
respective businesses, officers or employees.

 

Section 7.6 Company.

 

For
the purposes of Sections 7.1 to 7.5, references to the “Company” shall be deemed to include the Company, its Affiliates
and, its successors (whether direct or indirect) by purchase, amalgamation, merger or otherwise of the Business.

 

Section 7.7 Passive
Investments.

 

Nothing
in this Agreement shall prohibit or restrict the Executive from holding or becoming beneficially interested in up to ten percent
(10%) of any class of securities in any corporation provided that such class of securities are listed on a recognized stock exchange
in Canada or the United States.

 

     

     

    

 

ARTICLE 8– DIRECTORS
AND OFFICERS LIABILITY

 

Section 8.1 Directors
and Officers Liability.

 

During and after the term of this Agreement, the
Company shall:

 

(1)           maintain for the Executive’s benefit directors and officers liability insurance in respect of the period during which
the Executive is a director at levels equivalent to that provided to other officers and directors of the Company; and

 

(2)           indemnify
and hold the Executive harmless to the fullest extent permitted by applicable law with regard to any action or inaction of the
Executive provided:

 

		(a)	he acted honestly and in good faith with a view to the best interests of
the Company; and

 

		(b)	in the case of a criminal or administrative action or proceeding that is
enforced by a monetary penalty, he had reasonable grounds for believing that his conduct was lawful.

 

This Section 8.1 shall survive any termination of
this Agreement.

 

ARTICLE 9– REMEDIES

 

Section 9.1 Remedy.

 

The
Executive acknowledges and agrees that the Executive is employed in a fiduciary capacity, with obligations of trust and loyalty
owed by the Executive to the Company. Accordingly, the Executive agrees that the restrictions in Article 7 are reasonable in the
circumstances of the Executive’s employment and that the business and affairs of the Company cannot be properly protected
from the adverse consequences of the actions of the Executive other than by the restrictions set forth in this Agreement.

 

Section 9.2 Injunctions,
etc.

 

The
Executive acknowledges and agrees that, in the event of a breach of the covenants, provisions and restrictions in Article 7 by
the Executive, the Company’s remedy in the form of monetary damages will be inadequate. Therefore, the Company is hereby
authorized and entitled, in addition to all other rights and remedies available to it at law or in equity, to interim and permanent
injunctive relief and an accounting of all profits and benefits arising out of such breach without the necessity of posting a bond
or other security, and Executive consents to the entry of such relief.

 

Section 9.3 Loss
of Entitlements.

 

In addition
to all other rights and remedies available to the Company, the Executive acknowledges and agrees that the Executive will immediately
lose and not be entitled to the payments and benefits set out in Section 6.5(2)(b) (if applicable) which exceed the minimum entitlements
required by the Act if the Executive breaches any of the covenants in Article 7.

 

Section 9.4 Survival.

 

Each
and every provision of Article 1, Article 7, Article 8 and Article 9 shall survive the termination of this Agreement and the Executive’s
employment hereunder (regardless of whether such termination is voluntary or involuntary, lawful or unlawful and with or without
Just Cause).

 

     

     

    

 

ARTICLE 10 –
GENERAL CONTRACT TERMS

 

Section 10.1 Currency.

 

Unless
otherwise specified, all amounts payable pursuant to this Agreement are expressed in and shall be paid in Canadian currency.

 

Section 10.2 Withholding.

 

All
amounts paid or payable and all benefits, perquisites, allowances or entitlements provided to the Executive under this Agreement
are subject to applicable taxes and withholdings.

 

Section 10.3 Rights
and Waivers.

 

All
rights and remedies of the parties are separate and cumulative, and none of them, whether exercised or not, shall be deemed to
be to the exclusion of any other rights or remedies or shall be deemed to limit or prejudice any other legal or equitable rights
or remedies which either of the parties may have.

 

Section 10.4 Waiver.

 

Any purported
waiver of any default, breach or non-compliance under this Agreement is not effective unless in writing and signed by the party
to be bound by the waiver. No waiver shall be inferred from or implied by any failure to act or delay in acting by a party in respect
of any default, breach or non-observance or by anything done or omitted to be done by the other party. The waiver by a party of
any default, breach or non-compliance under this Agreement shall not operate as a waiver of that party’s rights under this
Agreement in respect of any continuing or subsequent default, breach or non-observance (whether of the same or any other nature).

 

Section 10.5 Severability.

 

Any provision
of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the
extent of the prohibition or unenforceability and shall be severed from the balance of this Agreement, all without affecting the
remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

 

Section 10.6 Notices.

 

Any notice
required or permitted to be given under this Agreement shall be in writing and shall be properly given if personally delivered,
delivered by electronic transmission or mailed by prepaid registered mail addressed as follows:

 

to the Company at:

Vireo Health International, Inc.

1330 Lagoon
Avenue, 5th Floor

Minneapolis, MN 55408 USA

Attention:
General Counsel

 

to the Executive at:

Bruce Linton

9 Shamrock Place

Ottawa, ON K2R 1A9 Canada

 

or to
such other address as the parties may from time to time specify by notice given in accordance herewith. Any notice so given shall
be conclusively deemed to have been given or made on the day of delivery, if personally delivered, or if delivered by electronic
transmission or mailed as aforesaid, upon the date the electronic transmission is sent or on the postal return receipt as the date
upon which the envelope containing such notice was actually received by the addressee.

 

     

     

    

 

Section 10.7 Successors
and Assigns.

 

This
Agreement shall inure to the benefit of, and be binding on, the parties and their respective heirs, administrators, executors,
successors (whether direct or indirect, by purchase, amalgamation, arrangement, merger, consolidation or otherwise) and permitted
assigns. The Company shall have the right to assign this Agreement, or the benefit thereof, to any of its Affiliates or to any
successor (whether direct or indirect, by purchase, amalgamation, arrangement, merger, consolidation or otherwise). The Executive,
by the Executive’s signature hereto, expressly consents to such assignment and, provided that such successor agrees to assume
and be bound by the terms and conditions of this Agreement, all references to the “Company” hereunder shall include
such successor. The parties agree that the services to be provided by the Executive are personal in nature, and therefore the Executive
shall not subcontract, assign or transfer, whether absolutely, by way of security or otherwise, all or any part of the Executive’s
rights or obligations under this Agreement.

 

Section 10.8 Amendment.

 

No amendment
of this Agreement will be effective unless made in writing and signed by both parties.

 

Section 10.9 Entire
Agreement.

 

This
Agreement, the warrant certificates representing the Incentive Warrants and the promissory note representing the Loan (collectively,
the “Agreement Documents”) constitute the entire agreement between the parties pertaining to the subject matter
of this Agreement and supersede all prior agreements, understandings, negotiations and discussions, whether oral or written with
respect to the Executive’s continued employment with the Company. There are no conditions, warranties, representations or
other agreements between the parties in connection with the subject matter of this Agreement (whether oral or written, express
or implied) except as specifically set out in the Agreement Documents.

 

Section 10.10 Governing
Law.

 

This
Agreement shall be governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada
applicable in that Province and shall be treated, in all respects, as an Ontario contract.

 

     

     

    

 

Section 10.11 Headings.

 

The division
of this Agreement into Sections and the insertion of headings are for convenience or reference only and shall not affect the construction
or interpretation of this Agreement.

 

Section 10.12 Independent
Legal Advice.

 

The
parties acknowledge that, prior to executing this Agreement, they have each had the opportunity to obtain independent legal advice
and that they fully understand the nature of this Agreement and that they are entering into this Agreement voluntarily.

 

Section 10.13
Counterparts.

 

This
Agreement may be executed in any number of counterparts, and delivered by facsimile or other means of electronic transmission,
each of which shall be deemed to be one and the same instrument and an original document.

 

Section 10.14
Ambiguities.

 

As
each party and its legal counsel have participated in the review and revision of this Agreement, any rule of construction to the
effect that ambiguities are to be resolved against the drafting party shall not apply in interpreting this Agreement.

 

(Signature Page Follows)

 

     

     

    

 

The
parties have executed this Agreement as of the date first written above.

 

	 	VIREO HEALTH INTERNATIONAL, INC.
	 	 
	 	By:	/s/ Kyle Kingsley
	 	 	Name: Kyle Kingsley
	 	 	Title: Chief Executive Officer

 

	 	/s/ Bruce Linton
	 	BRUCE LINTON

 

     

     

    

 

 

Schedule A –
[Intentionally deleted.]

 

[Intentionally deleted.]

 

    A - 1

     

    

 

Schedule B –
Promissory Note

 

GRID PROMISSORY NOTE

[l],
2020

 

1.                 
FOR VALUE RECEIVED, VIREO HEALTH INTERNATIONAL INC. (the “Lender”) agrees to lend to BRUCE
LINTON, an individual resident in the City of Ottawa, in the Province of Ontario (the “Borrower”), and the
Borrower promises to repay to or to the order of the Lender the unpaid principal balance of all advances made by the Lender to
the Borrower in accordance with the terms hereof (“Advances”), together with interest on such Advances as hereinafter
provided for, made by the Lender to the Borrower as recorded by the Lender on the grid attached as Schedule “A” hereto,
and if more than one grid is attached hereto, on the grids sequentially numbered and attached hereto (collectively, the “Grid”).

 

2.                 
This promissory note and the obligations hereunder shall become effective immediately upon the first exercise of any of
the first tranche incentive warrants issued to the Borrower by the Lender on November 6, 2019 (the “Warrants”)
and no Advances may be made pursuant to the terms hereof except for the sole purpose of funding the exercise price of Warrants
beneficially owned by the Borrower at the time such Warrants are exercised. This promissory note is being issued in connection
with the amended and restated employment agreement entered into between the Borrower and the Lender dated on or about the date
hereof and its terms shall be read in conjunction therewith.

 

3.                 
The Borrower shall pay interest on the principal balance of all Advances from time to time outstanding hereunder, from the
respective dates of such Advances to and including the dates of their respective repayment, at the rate of interest per annum equal
to two per cent (2%). Interest shall be due and payable at the time of the repayment of the Advances pursuant to Section 6 hereof.

 

4.                 
Interest at the aforesaid rate shall continue to be payable until the principal amount of each Advance has been repaid in
full and in case default shall be made in payment of any sum to become due for interest, compound interest shall be payable on
the sum in arrears for interest from time to time, as well after as before maturity, at the rate provided for herein.

 

5.                 
This promissory note shall evidence a running account of Advances and notwithstanding that the principal sum may be reduced
to zero or may show a credit in favour of the Borrower from time to time this promissory note shall continue in full force and
effect with respect to any Advances of the principal sum made thereafter. No Advance will be made by the Lender hereunder if such
Advance would result in the aggregate outstanding principal balance of all Advances being in excess of US$10,200,000 following
such Advance.

 

6.                  Entries
recorded by the Lender on the Grid shall, absent manifest error, be prima facie evidence of all amounts shown thereon, unless
within thirty (30) days of receipt of a copy of such entries, the Borrower claims and establishes that an error has been
made. Otherwise, such entries, absent manifest error, shall then be admissible in any proceedings as full and conclusive
evidence of such amounts and shall be binding on the Borrower to the same extent and effect as though the Borrower had
executed a separate promissory note for each of such entries. Notwithstanding the foregoing, entries of Advances made
pursuant to the terms of this promissory note shall be recorded by or on behalf of the Lender only following receipt by the
Lender of an advance request from the Borrower in the form attached hereto as Schedule “B” (each an
 “Advance Request”) and delivery by the Lender of the Advance requested by the Borrower in any such Advance
Request.

 

     

    - 2 -

    

 

7.                 
The principal amount of all Advances at any time outstanding, together with all accrued but unpaid interest as hereinbefore
provided for, shall be due and payable on the happening of any one of the following events, whichever first occurs:

 

		(a)	the commencement of any proceeding against the Borrower, whether voluntary
or involuntary or whether instituted by or against the Borrower, under the Bankruptcy and Insolvency Act (Canada) or any
other similar legislation of any jurisdiction seeking (i) an order declaring the Borrower insolvent or bankrupt or (ii) the appointment
(provisional, interim, or permanent) of any receiver, receiver and manager, trustee, monitor, custodian, liquidator; provided
however, that no such proceeding shall cause the amounts payable hereunder to become due and payable if it is being contested
by the Borrower in good faith by appropriate proceedings so long as enforcement remains stayed, none of the relief sought is granted
(either on an interim or permanent basis), and the proceeding is dismissed within 90 days of its commencement); or

 

		(b)	the Borrower fails to pay any interest required to be paid hereunder within
5 business days after the date such interest becomes due and payable.

 

In case
of any such event, at any time after its occurrence, the Lender may by written notice to the Borrower declare the whole of the
principal balance of all Advances made to the Borrower to be immediately due and payable (whereupon the same, together with accrued
interest thereon and any other sums owed by the Borrower hereunder, shall become so payable).

 

8.                 
Subject to any other agreement to the contrary, the Borrower shall be entitled to prepay all or any part or parts of the
principal sum at any time or times and from time to time without notice, penalty or bonus.

 

9.                 
Any amount paid hereunder shall be applied firstly in satisfaction of any accrued and unpaid interest and secondly in satisfaction
of the principal sum of Advances due hereunder. In the event the Lender obtains judgment on this promissory note, interest at the
aforesaid rate shall be payable on the amount outstanding under the said judgment.

 

10.             
The Borrower hereby waives the benefit of division and discussion, demand and presentment for payment, notice of nonpayment,
protest and notice of protest of this promissory note.

 

11.            
This promissory note may only be amended by a written document signed by each of the Lender and the Borrower.

 

12.              This
promissory note shall be governed by the laws in force in the Province of British Columbia and shall not be changed,
modified, discharged or cancelled orally or in any manner other than by agreement in writing signed by the Lender or its
heirs, executors, administrators, successors or assigns.

 

     

    - 3 -

    

 

13.             
The parties acknowledge that they have required that this agreement and all related documents be prepared in English.
Les parties reconnaissent avoir exigé que la présente convention et tous les documents connexes soient rédigés
en Anglais.

 

[SIGNATURE PAGE FOLLOWS]

 

     

     

    

 

DATED as of the date first above written.

 

 

	Signature of Witness	 	BRUCE LINTON

 

	 	VIREO HEALTH INTERNATIONAL, INC.
	 	 
		By:	
	 	 	Name:
	 	Title:
	 	 
	 	By:	
	 	 	Name:
	 	Title:

 

     

     

    

 

SCHEDULE “A”
TO GRID PROMISSORY NOTE

 

BETWEEN BRUCE LINTON
AND VIREO HEALTH INTERNATIONAL, INC.

 

DATED [l], 2020

 

	Date	Amount Advanced	Purpose	Amount

 Paid	Outstanding

 Balance	Notation

 by
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

 

     

     

    

 

SCHEDULE “B”
TO GRID PROMISSORY NOTE

 

BETWEEN BRUCE LINTON
AND VIREO HEALTH INTERNATIONAL, INC.

 

FORM OF ADVANCE REQUEST

 

	TO:	VIREO HEALTH INTERNATIONAL, INC. (the “Lender”)
	 
	FROM:	BRUCE LINTON (the “Borrower”)
	 
	DATE:

 

Reference
is made to the promissory note between the Borrower and the Lender (the “Promissory Note”) dated [l],
2020.

 

The
Borrower hereby requests that an advance be made in the amount of [$                 ] on [date] in accordance with the terms of the
Promissory Note.

 

Dated:
                                              

 

	 	 
	 	BRUCE LINTON

 

    B - 1

     

    

 

Schedule C –
Executive Information, Works, and/or Intellectual Property

 

None.

 

    C - 1

     

    

 

Schedule D –
Form 45-106F12

 

Risk Acknowledgement
Form for Family, Friend and

 

Business Associate Investors

 

	 	WARNING!	 
	 	 	 
	 	This investment is risky. Don’t invest unless you can afford to lose all the money you pay for this investment.	 

 

 

	SECTION 1 TO BE COMPLETED BY THE ISSUER
	1. About your investment
	Type of securities: Warrants to purchase subordinate voting shares of the Issuer	Issuer: VIREO HEALTH INTERNATIONAL, INC.
	SECTIONS 2 TO 4 TO BE COMPLETED BY THE PURCHASER
	2. Risk acknowledgement
	This investment is risky. Initial that you understand that:	Your

 initials
	Risk of loss – You could lose your entire investment of $ [N/A].	 
	Liquidity risk – You may not be able to sell your investment quickly – or at all.	 
	Lack of information – You may receive little or no information about your investment. The information you receive may be limited to the information provided to you by the family member, friend or close business associate specified in section 3 of this form.	 
	3. Family, friend or business associate status
	You must meet one of the following criteria to be able to make this investment. Initial the statement that applies to you:	Your

 initials
	 	 	 

    D - 1

     

    

 

	
        A)   
        You are:

         

        1)        
        [check all applicable boxes]

         

                      ̈    a director of the issuer or an affiliate of the
        issuer

         

        
                     x   an executive officer of the issuer or an affiliate of the issuer

         

                      ̈    a control person of the issuer or an affiliate of the issuer

         

                      ̈    a founder of the issuer

         

        OR

         

        2)        
        [check all applicable boxes]

         

         ̈    a person of which a majority of the voting securities
        are beneficially owned by, or a majority of the directors are, (i) individuals listed in (1) above and/or (ii) family members,
        close personal friends or close business associates of individuals listed in (1) above

         

         ̈    a trust or estate of which all of the beneficiaries
        or a majority of the trustees or executors are (i) individuals listed in (1) above and/or (ii) family members, close personal friends
        or close business associates of individuals listed in (1) above

         
	 
	
        B) You are a
family member of                                      [Instruction:
Insert the name of the person who is your relative either directly or through his or her spouse], who holds the following
position at the issuer or an affiliate of the issuer:                              .

         

        You are the                                    of that person or that person’s
        spouse.

         

        [Instruction: To qualify for this investment,
        you must be (a) the spouse of the person listed above or (b) the parent, grandparent, brother, sister, child or grandchild of that
        person or that person’s spouse.]

         
	 
	
        C) You are a close personal friend
        of                                     [Instruction:
        Insert the name of your close personal friend], who holds the following position at the issuer or an affiliate of
        the issuer:                             .
	 
	
        D) You are a close business associate
        of                                           [Instruction: Insert the name of your close business associate], who holds the following position
        at the issuer or an affiliate of the issuer:                             .
	 

 

    D - 2

     

    

 

	4. Your name and signature
	By signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified in this form. You also confirm that you are eligible to make this investment because you are a family member, close personal friend or close business associate of the person identified in section 5 of this form.

                                                                                 
	 
	First and last name (please print):

                                                                                 

	Signature:

                                                                                 
	Date:
	SECTIONS 5 TO BE COMPLETED BY PERSON WHO CLAIMS THE CLOSE PERSONAL RELATIONSHIP, IF APPLICABLE
	5. Contact person at the issuer or an affiliate of the issuer
	
        [Instruction: To be completed by
the director, executive officer, control person or founder with whom the purchaser has a close personal relationship indicated
under sections 3B, C or D of this form.]

         

        By signing this form, you confirm that you have,
        or your spouse has, the following relationship with the purchaser: [check the box that applies]

         

         ̈   family relationship as set out in section 3B of
        this form

         

         ̈   close personal friendship as set out in section
        3C of this form

         

         ̈   close business associate relationship as set out
        in section 3D of this form

         

	First and last name of contact person (please print):

                                                                                 

	Position with the issuer or affiliate of the issuer (director, executive officer, control person or founder):

                                                                                 

	Telephone:

                                                                                 
	Email:
	Signature:

                                                                                 
	Date:
	SECTIONS 6 TO BE COMPLETED BY THE ISSUER
	6. For more information about this investment
	 	 	 	 	 

    D - 3

     

    

 

	
        Vireo Health International,
        Inc.

        1330 Lagoon Avenue, 4th Floor

        Minneapolis, Minnesota

        55408

         

        Attn: Michael Schroeder, General Counsel and Chief
        Compliance Officer

        Phone: 612.314.8996

         

        michaelschroeder@vireohealth.com | vireohealth.com

         

        For more information about prospectus
        exemptions, contact your local securities regulator. You can find contact information at www.securities-administrators.ca.

         

	Signature of executive officer of the issuer (other than the purchaser):

                                                                                 
	Date:

 

    D - 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]